Stories

Removing business rates relief from vape shops risks treating harm reduction retailers as part of the problem rather than part of the solution. If specialist shops close or struggle, adult smokers may have fewer places to access advice, legal products and lower-risk alternatives to cigarettes. Policy should target irresponsible sales and youth access, not weaken the regulated market that helps people move away from combustion. Scotland should be making safer choices easier to find, not harder to sustain.

The US vape court battles show how contested the future of harm reduction has become. While cigarettes remain widely available, regulated vaping products face years of legal uncertainty, approval delays and enforcement disputes. For adult smokers, that means fewer reliable routes away from combustible tobacco. Public health policy should protect young people without keeping lower-risk alternatives trapped in a regulatory battleground.

The European Parliament’s rejection of steep nicotine tax proposals shows growing resistance to treating all nicotine products like cigarettes. Higher taxes on vapes, pouches and other smoke-free alternatives could weaken the incentive for smokers to switch away from combustible tobacco. Tax policy should reflect relative risk, not punish lower-risk choices. If Europe wants fewer smokers, it should not make safer alternatives less affordable.

Prohibition carries economic costs that go far beyond enforcement. When safer nicotine products are banned or heavily restricted, legal businesses lose ground, tax revenue declines and illicit markets gain power. Consumers are left with fewer regulated options while criminal networks benefit from demand that never disappeared. Harm reduction is not only a health strategy — it is also a way to keep safer products within accountable, legal markets.

The wrong public health question is whether vaping is risk-free. The right question is whether it can reduce harm for adult smokers who would otherwise continue using combustible cigarettes. Anti-vape arguments that ignore relative risk risk leaving people with the most dangerous option still on the table. Evidence-based policy should compare realistic choices, not ideal ones.

Vape flavour restrictions may weaken quit attempts by making lower-risk alternatives less appealing to adult smokers. Flavours can help people move away from the taste and ritual of cigarettes, supporting a clearer break from combustible tobacco. Protecting young people is essential, but broad flavour bans risk removing one of the tools that helps smokers switch. Evidence-based policy should target youth access without undermining adult cessation.

If most global vaping now sits outside legal markets, prohibition is not controlling nicotine use — it is losing control of it. Illicit supply leaves consumers with weaker safeguards, less product transparency and fewer age controls, while cigarettes often remain legally available. The lesson is straightforward: demand does not disappear when safer products are banned or overrestricted. Harm reduction needs regulated access, not black-market dependence.

New Zealand’s experience shows how quickly progress on smoking can become complicated when policy loses sight of harm reduction. Restrictive approaches may aim to reduce tobacco use, but they can also leave smokers with fewer practical routes away from combustible cigarettes. If lower-risk alternatives are limited, stigmatised or made harder to access, public health gains may be weakened rather than strengthened. Effective policy should reduce smoking-related harm while keeping realistic, regulated options available for people who need them.

Smokers deserve better than advice that treats vaping as no different from cigarettes. While no nicotine product is risk-free, public health guidance should clearly distinguish between combustible tobacco and smoke-free alternatives that reduce exposure to toxicants. When trusted institutions blur that distinction, smokers may be discouraged from switching to lower-risk options. Accurate risk communication is not a concession to nicotine — it is a necessary part of reducing smoking-related harm.

Poorly designed e-cigarette studies can do real damage when weak methods are turned into strong public health claims. If research fails to account for smoking history, product use patterns or the difference between association and causation, it risks misleading policymakers and the public. Vaping should be scrutinised, but the evidence must be held to serious scientific standards. Harm reduction policy should be guided by robust data, not studies that confuse risk rather than clarify it.